We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) ESTALIS 250/50 norethindrone acetate and estradiol 250/50 mcg/day transdermal therapeutic system (Canada)
Section 19A approved medicine
(Approval lapsed) ESTALIS 250/50 norethindrone acetate and estradiol 250/50 mcg/day transdermal therapeutic system (Canada)
Section 19A approval holder
Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Phone
1300 788 261
Approved until
Status
Expired
Medicines in short supply/unavailable
ESTALIS CONTINUOUS 50/250 estradiol 50mcg/day norethisterone acetate 250mcg/day patch sachet - ARTG 70817
Indication(s)
For the short-term treatment of symptoms of estrogen deficiency in menopausal women who have an intact uterus.
Images
